Shares of ABIOMED, Inc. (NASDAQ:ABMD) have received a consensus rating of “Buy” from the seven analysts that are presently covering the firm. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $147.00.

Several research analysts have commented on ABMD shares. BTIG Research restated a “buy” rating and issued a $170.00 target price on shares of ABIOMED in a research note on Sunday, January 8th. Guggenheim started coverage on ABIOMED in a research note on Tuesday, December 6th. They issued a “buy” rating and a $150.00 target price for the company. Zacks Investment Research downgraded ABIOMED from a “hold” rating to a “sell” rating in a research note on Thursday, January 5th. Finally, TheStreet upgraded ABIOMED from a “c+” rating to a “b-” rating in a research note on Tuesday, February 21st.

Hedge funds and other institutional investors have recently modified their holdings of the company. Palo Alto Investors LLC increased its position in ABIOMED by 1.0% in the fourth quarter. Palo Alto Investors LLC now owns 1,903,584 shares of the company’s stock valued at $214,496,000 after buying an additional 19,200 shares in the last quarter. BlackRock Fund Advisors increased its position in ABIOMED by 4.3% in the third quarter. BlackRock Fund Advisors now owns 1,631,879 shares of the company’s stock valued at $209,827,000 after buying an additional 66,809 shares in the last quarter. BlackRock Institutional Trust Company N.A. increased its position in ABIOMED by 1.4% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 1,177,198 shares of the company’s stock valued at $151,364,000 after buying an additional 16,224 shares in the last quarter. William Blair Investment Management LLC increased its position in ABIOMED by 36.0% in the fourth quarter. William Blair Investment Management LLC now owns 1,029,366 shares of the company’s stock valued at $115,989,000 after buying an additional 272,428 shares in the last quarter. Finally, Brown Capital Management LLC increased its position in ABIOMED by 16.2% in the fourth quarter. Brown Capital Management LLC now owns 701,811 shares of the company’s stock valued at $79,080,000 after buying an additional 97,847 shares in the last quarter. Institutional investors and hedge funds own 92.67% of the company’s stock.

ABIOMED (NASDAQ:ABMD) opened at 123.59 on Thursday. The stock has a 50 day moving average price of $114.86 and a 200 day moving average price of $116.38. The firm has a market cap of $5.37 billion, a P/E ratio of 115.61 and a beta of 0.51. ABIOMED has a 1-year low of $85.68 and a 1-year high of $132.95.

ABIOMED (NASDAQ:ABMD) last issued its earnings results on Thursday, January 26th. The company reported $0.34 EPS for the quarter, topping the consensus estimate of $0.29 by $0.05. ABIOMED had a return on equity of 12.35% and a net margin of 11.63%. The business earned $114.70 million during the quarter, compared to the consensus estimate of $112.71 million. During the same quarter last year, the company earned $0.23 EPS. The firm’s revenue was up 33.1% compared to the same quarter last year. On average, analysts anticipate that ABIOMED will post $1.18 EPS for the current year.

Your IP Address:

About ABIOMED

ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.

5 Day Chart for NASDAQ:ABMD

Receive News & Ratings for ABIOMED Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED Inc. and related companies with MarketBeat.com's FREE daily email newsletter.